Targeted protein degradation (TPD) has emerged as an exciting new era in chemical
biology and drug discovery. PROteolysis TArgeting Chimera (PROTAC) technology targets …

The technology known asPROTACs (PROteolysisTArgeting Chimeras) is a method of
protein degradation. Utilising bifunctional small molecules, the ubiquitin-proteosome system …

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

PROTACs are heterobifunctional small molecules that simultaneously bind a target protein
and a ubiquitin ligase, enabling ubiquitination and degradation of the target. Major progress …

The ubiquitin-proteasome system plays a central role in regulating protein homeostasis in
mammalian cells. It is a multistep process involving the polyubiquitination of proteins prior to …

Selective degradation of proteins by proteolysis targeting chimeras (PROTACs) offers a
promising potential alternative to protein inhibition for therapeutic intervention. Current …

With the discovery of PROteolysis TArgeting Chimeras (PROTACs) twenty years ago,
targeted protein degradation (TPD) has changed the landscape of drug development …

Targeted degradation approaches such as proteolysis targeting chimeras (PROTACs) offer
new ways to address disease through tackling challenging targets and with greater potency …

Abstract Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted
proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic …

Proteolysis targeting chimeras (PROTAC) represents a new type of small molecule induced
protein degradation technology that has emerged in recent years. PROTAC uses …